A phase 3 multicenter study to assess the efficacy and safety of etanercept 50 mg twice weekly in psoriasis

Trial Profile

A phase 3 multicenter study to assess the efficacy and safety of etanercept 50 mg twice weekly in psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Etanercept (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 03 Aug 2017 Results of pooled analysis of 10 trials (NCT00245960, NCT00111449, NCT00663052, NCT00454584) generating evidence concerning the number of patients dropping out of etanercept trials published in the British Journal of Dermatology
    • 08 Feb 2011 Results presented at the 69th Annual Meeting of the American Academy of Dermatology.
    • 19 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top